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Enterotoxigenic Escherichia coli Secretes a Highly Conserved
Mucin-Degrading Metalloprotease To Effectively Engage Intestinal
Epithelial Cells
Qingwei Luo,a Pardeep Kumar,a Tim J. Vickers,a Alaullah Sheikh,b Warren G. Lewis,a David A. Rasko,d Jeticia Sistrunk,d
James M. Fleckensteina,b,c
Department of Medicine, Division of Infectious Diseases,a and Molecular Microbiology and Microbial Pathogenesis Program, Division of Biology and Biomedical Sciences,b
Washington University School of Medicine, St. Louis, Missouri, USA; Medicine Service, Veterans Affairs Medical Center, St. Louis, Missouri, USAc; Institute for Genome
Sciences, Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USAd
Enterotoxigenic Escherichia coli (ETEC) is a leading cause of death due to diarrheal illness among young children in developing
countries, and there is currently no effective vaccine. Many elements of ETEC pathogenesis are still poorly defined. Here we dem-
onstrate that YghJ, a secreted ETEC antigen identified in immunoproteomic studies using convalescent patient sera, is required
for efficient access to small intestinal enterocytes and for the optimal delivery of heat-labile toxin (LT). Furthermore, YghJ is a
highly conserved metalloprotease that influences intestinal colonization of ETEC by degrading the major mucins in the small
intestine, MUC2 andMUC3. Genes encoding YghJ and its cognate type II secretion system (T2SS), which also secretes LT, are
highly conserved in ETEC and exist in other enteric pathogens, including other diarrheagenic E. coli and Vibrio cholerae bacte-
ria, suggesting that this mucin-degrading enzymemay represent a shared virulence feature of these important pathogens.
Enterotoxigenic Escherichia coli (ETEC) bacteria are a diversegroup of organisms that share the ability to secrete and effec-
tively deliver heat-stable toxin (ST) and/or heat-labile toxin (LT)
enterotoxins (1). Collectively, these organisms cause millions of
infections and are one of the leading pathogens associated with
death following moderate to severe diarrhea in young children
(2–4). In the classical paradigm for ETEC pathogenesis, these or-
ganisms adhere to the small intestinal mucosa via plasmid-en-
coded antigens known as colonization factors (CFs). At this site,
ETEC bacteria deliver toxins to receptors on epithelial cells.
Bound toxin increases host cell cyclic nucleotide concentrations,
activating the cystic fibrosis transmembrane regulatory channel
(CFTR) and ultimately culminating in fluid efflux into the intes-
tinal lumen (1).
Most ETEC vaccine development has focused on a subset of
antigens, including CFs and LT (5). Unfortunately, lack of ST
immunogenicity, incomplete protection afforded by LT immuni-
zation, and substantial antigenic heterogeneity of the CFs (6) have
hindered the development of a broadly protective ETEC vaccine.
However, the recent discovery of novel ETEC antigens (7, 8), the
complex nature of immune responses to infection (9), and the
modulation of many bacterial genes during infection (10) suggest
that neither molecular pathogenesis nor the nature of the protec-
tive immune response following infection with these pathogens is
completely understood.
For instance, while direct engagement of intestinal epithelial
cells is essential for efficient toxin delivery by ETEC (11), the vir-
ulence features contributing to this process are still poorly de-
fined. Interestingly, in the intestine, access of pathogens to entero-
cytes is largely limited by intestinal mucins, including MUC2 (12),
the major mucin secreted into the lumen of the intestine, as well as
cell-surface-bound mucins, including MUC3 (13). While many
enteric pathogens, including Vibrio cholerae and other diarrhea-
genic E. coli, secrete enzymes that degrade mucin, these enzymes
had not previously been identified in ETEC.
The present studies suggest that YghJ, a conserved (14, 15)
secreted molecule highlighted in recent immunoproteome (9)
and transcriptome (10) analysis of ETEC, is a mucin-binding met-
alloprotease that degrades intestinal mucins, including MUC2
and MUC3 to promote access of ETEC to enterocytes, thereby
accelerating efficient delivery of the heat-labile toxin to cognate
receptors on the epithelial surface.
MATERIALS AND METHODS
Maintenance and propagation of human cell lines. LS174T cells (Amer-
ican Type Culture Collection [ATCC] CL-188) were propagated in Eagle’s
minimum essential medium supplemented with 10% (final concentra-
tion) of fetal bovine serum (FBS). Caco-2 intestinal epithelial cells were
maintained in Eagle’s minimum essential medium containing FBS (20%
[vol/vol]). Jurkat cells were propagated in RPMI 1640 medium supple-
mented with FBS (10%). All cells were maintained at 37°C in 5% CO2.
Bacterial strains and growth conditions. Bacterial strains used are
listed in Table 1. In most experiments, ETEC bacteria were grown in Luria
broth at 37°C overnight from frozen glycerol stocks. To optimize secre-
tion of YghJ via the type II secretion system (T2SS), bacteria were grown in
Casamino Acids-yeast extract medium (CAYE) (11).
Cloning, expression, andpurification of recombinantYghJ. yghJwas
amplified from E. coli H10407 genomic DNA using primers jf031912.1
(5=-tccgagctcgagatccTTGTCACTTGCGTTATTAATGAATAAG-3= [na-
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tive ETEC sequence is capitalized; XhoI site underlined]) and jf031912.2
(5=-cccaagcttcgaattCTCGGCAGACATCTTATGCTC-3= [HindIII site
underlined]) for directional cloning into XhoI and HindIII sites in
pBAD/myc-HisA to create pQL001. E. coli TOP10(pQL001) was then in-
duced with arabinose to express recombinant YghJ tagged with myc and
polyhistidine (rYghJ-myc-His6), and the fusion protein was purified from
clarified lysates to homogeneity by nickel affinity chromatography, fol-
lowed by gel filtration chromatography (HiLoad 16/60 Superdex 200 prep
grade; GE Life Sciences) (10). Recombinant proteins with mutations in
the putative metalloprotease domain were purified similarly. Chelation of
metal ions from the recombinant protein to produce the apoenzyme was
performed by dialyzing 500 g of rYghJ overnight at 4°C against 1 liter of
phosphate-buffered saline (PBS) containing 10 mM EDTA, 1 mM 1,10-
phenanthroline, and 1 g Chelex 100 resin (Na form). Phenanthroline
was then removed by dialysis for 3 h against 1 liter of PBS containing 1
mM EDTA and 1 g Chelex resin. YghJ holoenzyme was then reconstituted
by adding 2 mM ZnSO4, NiSO4, or MgSO4 and incubating (5 min) at
room temperature.
Bioinformatic analysis of YghJ and T2SS sequences. Domain en-
hanced lookup time accelerated BLAST (Delta-BLAST) searches were
used to identify potential functional domains within YghJ (16). Protein
homology/analogy recognition engine (Phyre2) was then used to com-
pare regions of YghJ with libraries of known protein structures to further
elucidate potential functional residues (17).
BLASTN was used to query multiple draft ETEC genomes emerging from
an ongoing project to sequence multiple clinical isolates (http://gscid.igs.uma
ryland.edu/wp.php?wpcomparative_genome_analysis_of_enterotoxigenic
_e._coli_isolates_from_infections_of_different_clinical_severity).
Mutagenesis of the putative M60/pf13402 metallopeptidase do-
main. Site-directed mutagenesis of the native yghJ gene fragment carried
on pQL001 was performed by high-fidelity PCR using mutagenic primer
sets as indicated in Table 2. Mutagenized plasmids were then used to
transform E. coli TOP10 to ampicillin resistance. Mutations were con-
firmed by sequencing using primers jf101812.3 (5=-CCGAAGAAGAACC
TGAATGC-3=) and jf101812.4 (5=-TTACCGTTGGATTCAGCACA-3=).
Production and purification of polyclonal antibody. Polyclonal an-
tisera against rYghJ-myc-His6 were produced in rabbits as previously de-
scribed (8). Antibodies to YghJ were prepared by cross absorption of
resulting antisera against an immobilized E. coli lysate column (Thermo
Scientific) followed by affinity purification using the recombinant protein
immobilized on nitrocellulose membranes (18, 19).
Purification of MUC2. MUC2 was purified from supernatants of tis-
sue culture medium from LS174T cells (ATCC CL-188), a goblet cell-like
adenocarcinoma line that makes abundant MUC2 (20, 21). Briefly,
LS174T cells were grown as described above; conditioned medium was
recovered, concentrated by ultrafiltration using a 100-kDa-molecular-
weight-cutoff filter (MWCO), and then buffer exchanged with 10 mM
Tris-HCl and 250 mM NaCl (pH 7.4) prior to size exclusion chromatog-
raphy using Sepharose CL-2B resin (22). Fractions were checked for
MUC2 by anti-MUC2 dot immunoblotting. MUC2-positive fractions,
corresponding to a protein peak in the column void volume, were sepa-
rated on 3 to 8% Tris-acetate gradient gels, stained with Sypro Ruby to
check purity, and immunoblotted using anti-MUC2 to verify the identity
of the protein. Fractions containing intact, full-length MUC2 were then
pooled and saved at80°C for subsequent assays.
Protein interaction studies. To examine interaction of YghJ with the
human intestinal mucin MUC3, lysate from Caco-2 cells containing
MUC3 was separated by SDS-PAGE as described above and transferred to
nitrocellulose membranes. To examine interaction with MUC2, purified
protein was spotted on nitrocellulose membranes. Far Western analysis
was then performed with purified rYghJ-myc-His6. Briefly, nitrocellulose
membranes with immobilized mucins were blocked for 1 h with 1% bo-
vine serum albumin (BSA) in PBS before incubating with 50 g/ml of
purified rYghJ-myc-His6 overnight at 4°C. Proteins were detected by im-
munoblotting using antimucin antibodies as described below or anti-
YghJ antibody affinity purified from rabbit serum.
Mucin degradation studies. To examine the activity of YghJ against
the cell-associated mucin MUC3, we followed a protocol similar to that
described by Szabady et al. (23). Briefly, Caco-2 epithelial cell monolayers
were grown in 96-well tissue culture plates for 48 to 72 h postconfluence to
optimize MUC3 expression (20) on the epithelial surface. Supernatant
was removed and replaced with 100 l of minimum essential medium
(MEM) containing rYghJ-myc-His6 at a final concentration of 50 g/ml.
Following overnight treatment of the cell monolayers at 37°C and 5%
CO2, the medium was removed, and the monolayers were lysed in 20l of
lysis buffer (50 mM sodium phosphate, 250 mM NaCl, 0.1% Triton
TABLE 1 Bacterial strains and plasmids used in these studies




H10407 Wild-type ETEC strain O78:H11; CFA/1; LT/ST; EtpA 56, 57
E24377A WT ETEC strain O139:H28 58
B7A WT ETEC strain O148:H28 59
Nissle 1917 O6:H1 probiotic strain originally isolated from an asymptomatic German soldier 32
HS Isolated from a healthy adult scientist at WRAIR; O9:H4; motile 31
jf1123 H10407 derivative with isogenic deletion of gspE 11
jf1124 H10407 derivative with isogenic deletion of gspM 11
jf1121 H10407 derivative with isogenic deletion of gspG 11
TOP10 FmcrA (mrr-hsdRMS-mcrBC) 80lacZM15 lacX74 recA1 araD139 (ara leu)7697 galU galK rpsL (Strr) Invitrogen
yghJ mutant Isogenic insertion in yghJ; Kmr Cmr 14
Plasmids
pBAD/Myc-HisA Arabinose-inducible expression plasmid Invitrogen
pQL001 yghJ cloned into XhoI and HindIII sites of pBAD/myc-HisA in frame with myc-His tags This study
pQL117* Site-directed mutation of yghJ in codon corresponding to E1309(D) This study
pQL114* Site-directed mutation of yghJ in codon corresponding to E1309(A) This study
pQL150* Site-directed mutation of yghJ in codon corresponding to H1308(A) This study
pQL152* Site-directed mutation of yghJ in codon corresponding to H1312(A) This study
pQL124* 66-nucleotide in-frame deletion in yghJ This study
a Mutagenized yghJ plasmids (indicated by asterisks) used plasmid pQL001 as a template for mutagenesis.
b WRAIR, Walter Reed Army Institute of Research; Strr, streptomycin resistant; Kmr, kanamycin resistant; Cmr, chloramphenicol resistant.
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X-100, 0.1 mM phenylmethylsulfonyl fluoride [PMSF], and complete
EDTA-free protease inhibitor cocktail [Roche]). Following incubation on
ice for 30 min and repeated freeze (dry ice)-thaw (37°C) cycles, the lysates
were centrifuged at 10,000 g (4°C) to pellet debris. Clarified lysates were
then separated on gradient (3 to 8% Tris-acetate; Invitrogen) PAGE. Fol-
lowing transfer to nitrocellulose membranes, Caco-2 lysates were immu-
noblotted with anti-MUC3A/B goat polyclonal IgG antibodies (F-19 [cat-
alog no. sc-13314; Santa Cruz]) that recognize an internal region of mucin
3A of human origin (gene identification [ID] 4584).
To examine degradation of purified MUC2, 0.1 g of protein was
treated for at least 30 min with 5 g of rYghJ-myc-His6 at 37°C. Reaction
products were resolved by SDS-PAGE, and MUC2 digests were examined
with anti-MUC2 rabbit polyclonal (IgG) (H-300 [catalog no. sc-15334;
Santa Cruz]) that recognizes an epitope corresponding to amino acids
4880 to 5179 at the C terminus of human mucin 2 (gene ID 4583).
Degradation of MUC2 by LS174T cells was examined by incubating
cells grown on coverslips with purified recombinant YghJ for 3 h. MUC2
remaining after treatment was detected by immunofluorescence confocal
microscopy as described below, and images were saved as z-stacks. Image
data were then analyzed using Volocity three-dimensional (3D) image
analysis software (version 6.2; PerkinElmer, Inc.).
To determine whether YghJ degrades the mucin-like CD43 glycopro-
tein on the surfaces of human T lymphocytes, we followed a protocol
similar to that outlined by Szabady et al. (23). Briefly, 1 106 Jurkat cells
were incubated for 3 h at 37°C and 5% CO2 with 5 g of YghJ suspended
in a total volume of 100l of RPMI 1640 medium. The cells were pelleted
at 400 g for 5 min, washed with PBS, and blocked with 1% BSA in PBS,
and then cell surface CD43 was labeled with phycoerythrin-conjugated
anti-CD43 (mouse anti-human CD43 monoclonal clone L10; Invitrogen)
and analyzed by flow cytometry.
To test the activity of YghJ in degrading other substrates, we examined
the hydrolysis of fluorescein-labeled proteins (24). Quenched substrates,
including IgG, gelatin, and bovine submaxillary mucin (BSM) were pre-
pared by labeling with fluorescein isothiocyanate (FITC) (Sigma) as pre-
viously described (24). Casein-FITC was purchased from Sigma. Briefly,
10l of YghJ (50g) was added to 90l of 0.1 mg/ml substrate in 100 mM
Tris (pH 7.5) in black 96-well U-bottom polypropylene plates. The plates
were sealed with optically clear film (TempPlate; USA Scientific) and in-
cubated at 37°C, and fluorescence was measured every 5 min for several
hours on a Tecan F200 plate reader using an excitation filter at 485 nm and
an emission filter at 535 nm. Increase in fluorescence due to release of
quenched FITC upon proteolysis was tested using the protease subtilisin
as a positive control (0.1 to 1 mg/ml stock).
In vitro assessment of toxin delivery and binding. Caco-2 epithelial
cell monolayers were infected with ETEC H10407, yghJ mutants, or com-
plemented mutants at multiplicities of infection of approximately 100
(bacteria/cell). Cultures of bacteria were grown overnight in Luria broth
from frozen glycerol stocks, diluted 1:100, and grown for 1 h. One micro-
liter of each culture with or without antibodies as indicated in the figures
was then added to confluent Caco-2 monolayers seeded into 96-well
plates. Cultures of mutants complemented with pBAD-based expression
plasmids were supplemented with 0.0002% arabinose. Two hours after
inoculation, the monolayers were washed 3 times with tissue culture me-
dium, and the medium was replaced with 100 l of fresh medium/well
and returned to the incubator (37°C, 5% CO2) for 2.5 h. As previously
described, we used a cyclic AMP (cAMP) enzyme immunoassay (EIA)
(Arbor Assays, Ann Arbor, MI) (11) to examine the efficiency of toxin
delivery.
To examine the effect of YghJ on toxin access to cell surface receptors
on enterocytes, cells were treated with fluorophore-conjugated cholera
toxin B subunit. Briefly, Caco-2 or LS174T cells grown on coverslips were
treated with YghJ at a final concentration of 25 g/ml for 3 h at 37°C and
5% CO2. Following treatment, cell membranes were stained with Cell-
Mask (catalog no. C10046; Life Technologies) and then fixed with 2%
paraformaldehyde for 10 min. After the cells were blocked with 1% BSA,
they were labeled with cholera toxin subunit B conjugate (catalog no.
C34775; Life Technologies). Images were acquired by fluorescence con-
focal microscopy with z-stacks, and signal data were then analyzed using
Volocity 3D image analysis software (version 6.2; PerkinElmer, Inc.).
Mouse intestinal colonization and competition assays.Colonization
of the ileum of infected mice was assessed using the CD-1 mouse intestinal
colonization model (25). Briefly, mice were pretreated with streptomycin;
the mice were given streptomycin (5 g/liter) in drinking water for 24 h,
followed by drinking water alone for 12 h. After the administration of
famotidine (50 mg/kg of body weight) to reduce gastric acidity, mice were
challenged with approximately 105 CFU of either the lacZYA::Kmr strain
or the yghJ::Kmr mutant by oral gavage. Twenty-four hours later, the mice
were sacrificed, and dilutions of saponin intestinal lysates were plated
TABLE 2 Oligonucleotides used in these studies
Primer Sequence (5=¡3=)a Description
jf031912.1 TCCGAGCTCGAGATCCTTGTCACTTGCGTTATTAATGAATAAG
(XhoI site underlined)
yghJ forward cloning primer
jf031912.2 CCCAAGCTTCGAATTCTCGGCAGACATCTTATGCTC (HindIII
site underlined)
yghJ reverse cloning primer
jf082312.1 GCTGATCTGGCATGATGTCGGTCATAACGCC (GAA¡GAT
mutation underlined)
Site-directed mutagenesis (E1309D) forward
jf082312.2 GGCGTTATGACCGACATCATGCCAGATCAGC Site-directed mutagenesis (E1309D) reverse
jf082312.3 GGCTGATCTGGCATGCAGTCGGTCATAACGC (GAA¡GCA
mutation underlined)
Site-directed mutagenesis (E1309A) forward
jf082312.4 GCGTTATGACCGACTGCATGCCAGATCAGCC Site-directed mutagenesis (E1309A) reverse
jf112612.1 ACGACTGGCTGATCTGGGCTGAAGTCGGTCATAACG
(CAT¡GCT mutation underlined)
Site-directed mutagenesis (H1308A) forward
jf112612.2 CGTTATGACCGACTTCAGCCCAGATCAGCCAGTCGT Site-directed mutagenesis (H1308A) reverse
jf112612.3 CTGGCATGAAGTCGGTGCTAACGCCGCAGAAACG
(CAT¡GCT mutation underlined)
Site-directed mutagenesis (H1312A) forward
jf112612.4 CGTTTCTGCGGCGTTAGCACCGACTTCATGCCAG Site-directed mutagenesis (H1312A) reverse
jf101712.1 GACTGGCTGATCTGG(66)AACGTGCTGGCGCTG Mutagenesis primer to construct 22-amino-acid internal
deletion of YghJ residues H1308 to N1329
jf101712.2 CAGCGCCAGCACGTT(66)CCAGATCAGCCAGTC Reverse complement of jf101712.1
jf101812.3 CCGAAGAAGAACCTGAATGC Forward sequencing primer yghJ from nt 3616 to 3635
jf101812.4 TTACCGTTGGATTCAGCACA Reverse sequencing primer yghJ from nt 4319 to 4300
a (66) indicates the position of the 66-nucleotide in-frame deletion in yghJ extending from nucleotide (nt) 3904 to 3969.
YghJ Is a Conserved Mucin-Degrading Metalloprotease
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onto Luria agar plates containing kanamycin (25 g/ml). Competition
assays were performed in a similar manner by simultaneous challenge
with approximately 104 CFU of each strain. After 24 h, lysates were plated
onto agar containing kanamycin and 5-bromo-4-chloro-3-indolyl-	-D-
galactopyranoside (X-Gal) to identify wild-type (WT) (lacZYA::Kmr)
(white) or yghJ mutant (blue) colonies. In mouse intestinal colonization
studies to examine penetration of the mucous layer, mice were inoculated
with 108 CFU of either WT H10407 or the yghJ mutant, and after 24 h,
mice were sacrificed, and samples were fixed in formalin or Carnoy’s
solution to preserve the mucin layer.
Immunohistochemistry. Sections of small intestine were preserved in
formalin, embedded in paraffin, and cut into 4-m sections for further
processing. Following removal of paraffin, sections were immunostained
overnight at 4°C with anti-MUC2 rabbit polyclonal antibody (ab76774;
Abcam) (1:100), followed by goat anti-rabbit biotinylated secondary an-
tibody (Jackson ImmunoResearch Laboratories; 1:800) and streptavidin-
horseradish peroxidase (HRP) conjugate (catalog no. 016-030-084;
Jackson ImmunoResearch Laboratories) (1:1,600). Samples were then de-
veloped with 3,3=-diaminobenzidine (Betazoid DAB; Biocare) and coun-
terstained with hematoxylin. Light microscopic images were acquired
using a Zeiss Axioscope microscope fitted with an Axiocam HRm cam-
era or a Zeiss Axioskop 2 MOT microscope fitted with a CRI Nuance
FX multispectral imaging system (Cambridge Research and Instru-
mentation).
Immunofluorescence microscopy. To identify ETEC H10407 (sero-
type O78:H11) in the intestine, sections were incubated with anti-O78
antisera obtained from the E. coli Reference Center at Pennsylvania State
University, followed by fluorophore Alexa Fluor goat anti-rabbit conju-
gates. MUC2 in mouse intestinal sections was identified using anti-MUC2
mouse monoclonal antibody (clone 966/1) (ab11197; Abcam). Confocal
microscopy images were obtained in the Molecular Microbiology Imag-
ing Facility using a Zeiss LSM 510 Meta confocal laser scanning micro-
scope.
To identify cAMP in sections of mouse small intestine, sections were
first stained with CellMask orange (catalog no. C10045; Life Technolo-
gies) diluted 1:2,000 for 5 min at 37°C, blocked in 1% BSA for 30 min at
37°C, then labeled with anti-cAMP rabbit polyclonal antibody (catalog
no. 07-1497; Millipore) diluted 1:100 for 1 h. After the sections were
washed, goat anti-rabbit–Alexa Fluor 488 conjugate was added at 1:200
for 30 min. After the sections were washed and incubated with TO-PRO-3
nucleus counterstain (1:250) for 15 min at room temperature, coverslips
were mounted with Prolong gold. To quantify fluorescence, intensity Im-
FIG 1 YghJ is a highly conserved type II secretion system (T2SS) effector molecule that facilitates delivery of heat-labile toxin (LT). (a) The product of the yghJ
gene, located upstream of the T2SS genes responsible for secretion of the heat-labile toxin as shown in panel a is secreted by ETEC strains with an intact T2SS. (b)
Immunoblot demonstrating YghJ in trichloroacetic acid (TCA) precipitates of overnight cultures of ETEC strains H10407, B7A, and E24377A, but not the yghJ
mutant, T2SS mutants (gspG, gspE, and gspM), or strain MG1655 (E. coli K-12), which has a truncated version of yghJ and lacks most T2SS genes. Commensal
strains HS and Nissle 1917 secrete comparatively little YghJ. (c) Flow cytometry data demonstrating that some YghJ remains associated with the surface of strain
H10407 (serotype O78:H11; top right panel) but not with the yghJ mutant (bottom right panel). The regions enclosed in rectangles show the areas gated for
surface expression, and the number in the top right-hand corner of each panel represents the percentage of positive cells for the respective antigen under
consideration. Anti-O78 (
-O78) data are included as positive controls for surface expression. 1° Ab, primary antibody; 2° Ab, secondary antibody; 
-YghJ,
anti-YghJ antibody; AF488, Alexa Fluor 488. (d) Secretion of heat-labile toxin by ETEC is not affected by yghJ. GM1 ganglioside enzyme-linked immunosorbent
assay (ELISA) data for wild-type (wt) H10407 ETEC, yghJmutant, and complemented yghJmutant (pQL001) relative to the LT mutant (eltAB) are shown. OD450,
optical density at 450 nm. (e) cAMP production by target Caco-2 cells following infection with wild-type ETEC H10407, yghJ mutant, or complemented mutant.
The LT deletion mutant (eltAB) mutant is included here as a negative control. (f) Affinity-purified polyclonal antibodies (
) against YghJ (YghJ), but not
antibody preabsorbed with recombinant YghJ (YghJ) impair delivery of LT to target epithelial cells. Values that are significantly different (P 0.05) from each
other are indicated by a bar and asterisk (n 4; two-tailed Mann-Whitney analysis).
Luo et al.
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ageJ (v1.47) was used to measure the mean fluorescence per pixel (http:
//rsbweb.nih.gov/ij/docs/menus/analyze.html#measure). These values
were then normalized for the number of epithelial cells present in the
image.
FACS analysis and mucin accumulation studies. Fluorescence-acti-
vated cell sorting (FACS) analysis was used to determine the presence of
YghJ on the surfaces of ETEC (26). Briefly, bacteria suspended in phos-
phate-buffered saline (pH 7.2) were first fixed with 2% paraformaldehyde
for 15 min, washed twice in PBS, and blocked with 1% BSA in PBS for 30
min. The resulting cell suspensions were incubated with affinity-purified
anti-YghJ antibody in blocking solution for 1 h at room temperature,
washed three times, and then incubated with anti-rabbit antibody–Alexa
Fluor 594 conjugate.
To study binding of MUC2 to the surfaces of ETEC, supernatants
from overnight cultures of LS174T cells grown in confluent monolay-
ers were sterilized by filtration through a 0.22-m filter and then con-
centrated through a 100-kDa-molecular-weight-cutoff centrifugal
filter to concentrate MUC2 secreted into culture supernatants. Follow-
ing inoculation with bacteria, the infected MUC2-positive (MUC2)
retentate was incubated at 37°C and 5% CO2, and aliquots were re-
trieved at various time points. Following centrifugation at 10,000  g
and 4°C, the bacterial pellets were washed with PBS, fixed with 2%
paraformaldehyde for 15 min, washed again in PBS to remove the
fixative, blocked with 1% BSA in PBS, incubated with rabbit polyclonal
anti-MUC2 (1:50), and detected with goat anti-rabbit fluorescent (Al-
exa Fluor 488; Invitrogen) antibody conjugate. MUC2 binding to bac-
teria was then examined by flow cytometry (26). Flow cytometry data
were processed in FlowJo v10.0.5 (Tree Star, Inc.).
RESULTS
YghJ is required for efficient delivery of heat-labile toxin. YghJ,
encoded immediately upstream of the genes encoding the type II
secretion system (T2SS) that is responsible for export of the heat-
labile toxin (Fig. 1a) (27) was found in abundance in culture su-
pernatants of several ETEC strains, including H10407, B7A, and
FIG 2 YghJ is required for efficient access to the surfaces of enterocytes. (a) Total ETEC recovered from intestinal lysates following infection with either the
wild-type (wt) strain bearing a Kmr cassette insertion in the lacZYA locus (lacZYA::Kmr) or the yghJ::Kmr mutant. The bars show the geometric mean number
of CFU/ml. Each symbol shows the value for an individual mouse. (b) Competition assay between the lacZYA mutant and the yghJ mutant showing total bacteria
recovered from intestinal lysates (the bar represents the average competitive index). (c) Bacteria intimately associated with the surfaces of intestinal villi (n 100)
from intestinal segments of mice (n 2) following challenge with either H10407 (wt) (blue open circles), or the yghJ mutant (open squares) (P values reflect
two-tailed Mann-Whitney nonparametric analysis). (d to f) ETEC H10407 (serotype O78:H11) intimately associated with enterocyte surfaces of intestinal villi.
Bacteria identified by anti-O78 (red) immunofluorescence imaging are shown in the insets and in panel g. (h and i) Trapping of the yghJmutant in luminal mucus
(MUC2 is shown in red; bacteria identified by anti-O78 antibodies appear green). H10407 also appears in the lumen (j), but it is also present in close association
with the enterocyte surface (k and l).
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E24377A (Fig. 1b). However, in keeping with earlier studies sug-
gesting that YghJ is secreted by the T2SS in other E. coli pathotypes
(28), we did not find YghJ in culture supernatants of ETEC strains
with mutations in T2SS genes gspE, gspG, and gspM or in cultures
of E. coli MG1655 that lacks an intact T2SS (27). YghJ and the
T2SS proteins were also found on the chromosomes of nonpatho-
genic E. coli strains (29, 30) (see supplemental material) including
HS, an intestinal commensal strain previously isolated from a
healthy adult (31), and Nissle 1917, originally obtained from an
asymptomatic German soldier (32). However, relative to ETEC
strains, the amount of YghJ secreted by these strains was quite
small. Because we had previously detected YghJ in association
with outer membrane vesicles (9), we also examined the surface of
ETEC for YghJ by flow cytometry (Fig. 1c), revealing that some
YghJ also remains associated with the surface of wild-type strain
H10407. While YghJ export is dependent on T2SS, conversely,
mutation of yghJ had no impact on secretion of LT (14), and
likewise, trans-complementation of the mutant with a recombi-
nant YghJ expression plasmid (pQL001) did not affect toxin se-
cretion (Fig. 1d), suggesting that this molecule does not compete
with LT or facilitate its secretion. However, we noted that the yghJ
mutant was appreciably deficient in the ability to deliver LT as deter-
mined by the diminished activation of cAMP in target epithelial cells
(Fig. 1e). Likewise, affinity-purified antibodies against YghJ signifi-
cantly impaired delivery of LT by ETEC (Fig. 1f). Together, these
studies suggest that these type II secretion effectors, YghJ and LT, act
in concert to intoxicate enterocytes, leading to activation of cyclic
nucleotides that drive chloride secretion that results in diarrhea.
Intimate enterocyte engagement requires YghJ. YghJ shares
homology with accessory colonization factor D (AcfD), a lipopro-
tein (33) important for intestinal colonization of Vibrio cholerae
(34). Curiously, relative to ETEC (H10407) carrying a mutation in
the lacZYA locus, which does not affect intestinal colonization
(25), we actually recovered slightly more yghJ mutant organisms
from small intestinal lysates regardless of whether mice were chal-
lenged with the individual strains (Fig. 2a) (P 0.6) or together in
competition assays (Fig. 2b). Interestingly, however, microscopic
examination of ileal sections from mice challenged with either
strain H10407 or the yghJ mutant demonstrated many WT organ-
isms intimately associated with the surfaces of enterocytes (Fig. 2c
and Fig. 2d to g), while we could identify few if any yghJ mutant
organisms, suggesting that YghJ is required for bacteria to gain
efficient access to the intestinal epithelial cells (P 0.0001).
To gain access to the enterocyte surface, enteric pathogens
must transit through complex glycoproteins known as mucins.
Because there were few yghJ mutant organisms on the enterocyte
surface, we questioned whether these organisms have lost the abil-
ity to traverse the mucous layer in the small intestine. In the small
intestine, the major luminal mucin is MUC2 (13). In sections
fixed to retain luminal mucus (Fig. 2h to l), we identified many
FIG 3 Mucin accumulation on the surface of ETEC is accelerated in yghJ mutant bacteria. (a) Light microscopy image of MUC2 immunostained ETEC
intimately attached to the enterocyte surface following wild-type H10407 oral challenge. The image was acquired following immunostaining with MUC2
polyclonal antibody, biotinylated secondary antibody, streptavidin-HRP conjugate, and 3,3=-diaminobenzidine (Betazoid DAB; Biocare), counterstained with
hematoxylin. (b) Confocal microscopic images of ETEC H10407-infected mouse intestine demonstrating colocalization of MUC2 (red) with O78 antigen
(green) on the surface of ETEC. (c) MUC2 identified on the surfaces of luminal bacteria, in frozen sections of small intestine (green, MUC2; red, anti-O78; yellow,
merged images) following intestinal infection. (d) Wild-type (wt) ETEC H10407 (anti-O78, green) and yghJ mutant (anti-O78, green; nucleic acid, blue) in
plumes of MUC2 mucin (red) deposited over the surfaces of goblet cells (white arrows). (e) yghJ mutants exhibit excess accumulation of MUC2 relative to
wild-type H10407. Data represent MUC2 bacteria determined by flow cytometry following incubation in MUC2 supernatants from LS174T cells. The regions
enclosed in rectangles show the areas gated for surface expression, and the number in the top right-hand corner shows the percentage of MUC2 bacteria.
Luo et al.
514 iai.asm.org Infection and Immunity
 o
n
 April 20, 2014 by W







yghJ mutant bacteria within the MUC2 luminal mucous layer
(Fig. 2h and i), while WT organisms appeared both in the lumen
(Fig. 2j) and at the enterocyte surface (Fig. 2k and l).
Deletion of yghJ accelerates accumulation of mucin on the
surface of ETEC. In sections of intestine from mice challenged
with WT ETEC, we identified MUC2-coated bacteria inti-
mately associated with the mucosal surface by immunohisto-
chemistry (Fig. 3a) or by confocal microscopy where organisms
appeared labeled with both MUC2 and anti-O78 (Fig. 3b).
Similarly, for both the H10407 strain and the yghJ mutant,
luminal bacteria could be identified where MUC2 appeared in
close association with the surfaces of organisms (Fig. 3c). In
intestinal sections where efforts were made to preserve luminal
mucin, we observed both wild-type and yghJ mutant bacteria
(Fig. 3d) in plumes of MUC2 deposited over goblet cells. Be-
cause the yghJ mutant appeared to have limited access to the
mucosal surface, we questioned whether the kinetics of ETEC
association with MUC2 might differ. Following short incuba-
tion (1 h) with MUC2-containing conditioned medium, the
yghJ mutant was more frequently coated with MUC2 relative to
the wild-type ETEC strain (Fig. 3e). Collectively, these data
suggest that ETEC colonization of the small intestine relates in
FIG 4 YghJ is a metalloprotease that binds and degrades secreted and cell-bound intestinal mucins. (a) Potential motifs and domains within YghJ include a
potential LXGC lipoprotein motif at the amino-terminal end following the signal peptide, a domain of unknown function (DUF4092), and a M60-like peptidase
domain (pfam13402) at the carboxy-terminal end of the protein. Within this domain lies a putative HEXXH metalloprotease motif. (b) YghJ interacts with
purified MUC2. Shown in the anti-YghJ immunoblot are 10-fold dilutions of the bait proteins (MUC2 in the top row and the BSA control in the bottom row)
immobilized on nitrocellulose membranes prior to incubation with rYghJ-myc-His6. (c) YghJ degrades purified MUC2 as shown in the anti-MUC2 immunoblot.
In the rYghJ row below the blot, (1 indicates 5 g of rYghJ-myc-His6, while 
10 indicates 50 g rYghJ-myc-His6). The numbers to the right of the blot
indicate 3% stacking gel and 4% resolving gel. The position of the molecular mass marker (in kilodaltons) is indicated to the left of the blot. (d) Mutations in the
canonical metalloprotease motif located between H1308 and H1312 affect degradation of MUC2 as shown in the anti-MUC2 immunoblot. From left to right, the
lanes contain untreated MUC2 (ø) and MUC2 treated with either rYghJ or mutant proteins. (e and f) Composite images of MUC2-expressing LS174T cells
following treatment with rYghJ (e) or mock treatment control (f). MUC2 is shown in green, the membrane is shown in red, and the nuclei are shown in blue. (g)
Far Western immunoblots demonstrating interaction of rYghJ with MUC3 in Caco-2 cell intestinal lysates. Both lanes contain Caco-2 cell lysates. The left strip
was probed with rYghJ and developed with anti-YghJ antibody, while the right strip was developed with anti-MUC3 antibody. (h) Degradation of MUC3 on the
surfaces of Caco-2 cells by rYghJ or rYghJ with mutations in the putative metalloprotease motif. (i) YghJ exhibits features of metalloproteases. MUC3 signal from
untreated Caco-2 cells is shown in the leftmost lane of the immunoblot (ø lane). YghJ degradation of MUC3 (rYghJ lane) was prevented when equal amounts of
recombinant YghJ chelated with phenanthroline to remove metals was used to treat cells ( lane), while supplementation of chelated YghJ with divalent cations
(Zn2, Ni2, and Mg2) restored protease activity.
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part to its interactions with intestinal mucins and that YghJ
modulates these interactions.
YghJ specifically binds and degrades intestinal mucins.
Comparison of the predicted YghJ protein sequence to known
proteins demonstrated several potential functional domains or
motifs (Fig. 4a) including a N-terminal signal peptide, followed by
a putative lipoprotein (L-X-G-C) motif, a domain of unknown
function found in Proteobacteria (DUF4092) located at amino
acid residues 422 to 591 of YghJ, and finally an enhancin/M60-like
peptidase domain (pfam13402) at residues 1090 to 1386. Included
within the predicted peptidase domain is a putative HEXXH met-
alloprotease motif at positions 1308 to 1312. Enhancin (35) and
other members of this family bind to and degrade mucins or mu-
cin-like glycoproteins; therefore, we examined the ability of YghJ
to degrade mucins. YghJ bound to purified MUC2 (Fig. 4b), and
YghJ degraded this intestinal mucin in a dose-dependent fashion
(Fig. 4c). As predicted by the putative metalloprotease motif
within the peptidase domain, this activity was at least partially
inhibited by EDTA. Similarly, we found that YghJ degradation of
MUC2 was affected by mutagenizing the canonical metallopro-
tease motif. Further comparisons (17) suggested that a 22-amino-
acid region extending from H1308 to N1329 contained a potential
active site within YghJ, and mutant recombinant protein YghJ
with the region from H1308 to N1329 deleted [YghJ(H1309-
N1329)] demonstrated greatly reduced MUC2 mucinase activity
in vitro (Fig. 4d), while mutagenesis of individual residues within
the HEXXH motif partially prevented mucin degradation. To fur-
ther examine activity of YghJ, we studied LS174T cells, which
make abundant MUC2 (20). Treatment of cells with rYghJ signif-
icantly reduced the amount of extracellular MUC2 (Fig. 4e) rela-
tive to mock-treated controls (Fig. 4f). YghJ also appeared to in-
teract with the predominant cell-bound mucin in the small
intestine, MUC3 (Fig. 4g). In addition, YghJ degraded MUC3 on
the surfaces of intestinal epithelial cells in vitro (Fig. 4h), and deg-
radation at least partly depended on an intact HEXXH motif. Sim-
ilarly, chelation of metal from the recombinant protein by dialysis
against phenanthroline abolished mucinase activity, while supple-
mentation of divalent cations restored activity to the chelated pro-
tein (Fig. 4i). Together, these data suggested that YghJ is a member
of a family of metalloproteases that degrade mucins.
In contrast, YghJ was inactive against the mucin-like CD43
molecule expressed by Jurkat cells (Fig. 5a), bovine submaxillary
mucin, gelatin, or IgG (Fig. 5b). Collectively, these data suggest
that YghJ has specific activity for the major mucins in the verte-
brate lumen and on the surfaces of cells in the small intestine.
Conservation of YghJ features in peptides from E. coli andV.
cholerae. Interestingly, we found that YghJ and genes encoding
the downstream T2SS were highly conserved in ETEC and com-
mensal strains that have been sequenced (see Table S1 in the sup-
plemental material), as well as more recently sequenced O104:H4
Shiga toxin-producing enteroaggregative E. coli (36) (see Fig. S1a
and S1b in the supplemental material). In contrast to commensal
strains however, both the ETEC strains and the O104 strains se-
creted significant amounts of YghJ (Fig. S1c). The YghJ peptide is
currently annotated as a homologue of the Vibrio cholerae protein
AcfD. Alignments of YghJ and AcfD from Vibrio cholerae classical
6th pandemic and El Tor 7th pandemic strains demonstrated ex-
tensive homology (Fig. S1a and S1b); multiple common features
include the putative lipoprotein (LXGC) motif at their amino ter-
mini, the domain of unknown function, and the M60-like pepti-
dase domain where the metalloprotease motif sequence HEVGH
was completely conserved (Fig. 6).
YghJ is required for efficient toxin delivery to intestinal epi-
thelia. Because earlier studies showed that direct interaction with
epithelial cells is required for efficient delivery of heat-labile toxin
by ETEC (11), we postulated that degradation of mucins would
promote access of toxin to surface receptors. Accordingly, we
found that treatment of epithelial cells with YghJ significantly en-
hanced binding of labeled cholera toxin to the epithelial surface
(Fig. 7). Likewise, we reasoned that degradation of mucin in the
intestinal lumen would permit direct access of the bacteria to en-
terocytes and enhance LT-stimulated cAMP activation in target
epithelial cells. Indeed, we found substantial increases in cAMP
content of small intestinal epithelial cells following infection with
wild-type ETEC relative to those infected with the YghJ mutant or
unchallenged (PBS-challenged) control mice (Fig. 8).
As MUC2 forms a critical barrier that limits access of both patho-
gens and commensal organisms to the epithelial surface of the intes-
tine (13), it has been suggested that MUC2 contributes to elimination
of pathogens loosely associated with tissue, as they become trapped in
luminal mucin that is removed by peristaltic flow (12). Therefore, we
reasoned that in the absence of MUC2 mucinase activity provided by
YghJ, mutant bacteria would be more rapidly shed in stools. How-
ever, we did not observe consistent differences in fecal shedding fol-
FIG 5 rYghJ does not degrade other substrates. (a) YghJ does not degrade the mucin-like CD43 glycoprotein on the surfaces of Jurkat cells as shown in CD43 flow
cytometry. The two numbers are the percentages of CD43 cells in the two populations. (b) Fluorophore release assays using fluorescently labeled quenched
protein substrates demonstrate an increase in fluorescence following treatment with the general protease subtilisin but not with YghJ.
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lowing oral challenge with wild-type or yghJ mutant bacteria (data
not shown), perhaps suggesting that YghJ plays a more complex role
than simply degrading luminal gel-forming mucins or that it shares
this ability with other enzymes.
Collectively, however, these studies support the concept that
YghJ contributes significantly to the pathogenesis of ETEC, in part
by degrading intestinal mucin, thereby permitting these organ-
isms to overcome this important host defense mechanism. By de-
grading mucin, these organisms gain direct access to epithelial
cells required for efficient delivery of their toxin payload.
FIG 6 Alignment of sequences surrounding the putative metalloprotease motifs (shown in bold type) of YghJ from ETEC and similar proteins from other enteric
organisms. Individual strain designations are shown to the right of the sequences. These strains include Shiga toxin-producing E. coli serotype O104:H4 and
commensal E. coli strains HS, SE-11, and Nissle 1917. AcfD proteins from V. cholerae O1 strains include strain 2010 EL-1786 (El Tor biotype, 2010 Haiti isolate),
CP1030 (3) (Mexico), N16961 (prototypical 7th pandemic El Tor biotype), O395 classical O1 serotype (prototypical 6th pandemic, Ogawa biotype). (b) YghJ is
secreted by ETEC and E. coli O104 isolates, as shown by the immunoblot of TCA precipitates. The small black arrow at the top indicates the migration of YghJ.
The positions of molecular mass markers (in kilodaltons) are shown to the right of the gel.
FIG 7 YghJ enhances toxin access to enterocytes. (a) Quantitative immunofluorescence data demonstrating binding of fluorescently labeled cholera toxin
B-subunit (AF488-CTB) obtained following treatment of Caco-2 cells with rYghJ compared to mock-treated (ø) cells. (b) AF488-CTB binding to LS174T cells
is enhanced following rYghJ treatment. P 0.0001 by Mann-Whitney nonparametric comparison of treated and untreated cell populations. The fluorescence
data are normalized to the number of cell nuclei present in each field. (c and d) Images of CTB binding to LS174T cells are shown in panels c (untreated) and d
(YghJ treated). Figures represent merged images of membrane (CellMask [red]), and Alexa Fluor 488-conjugated CTB-green. Membrane images were decon-
volved in ImageJ, and brightness and contrast were adjusted for clarity, while AF-CTB images were not enhanced following acquisition.
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Fundamentally, the ETEC pathovar is defined by the ability to
produce and effectively deliver heat-labile toxin (LT) and/or heat-
stable toxin (ST) enterotoxins to epithelial receptors where they
then cause net fluid secretion and diarrhea (1). Most pathogenic
Escherichia coli, including ETEC, have relatively few pathovar-spe-
cific genes (30). Consequently, it has been suggested that little
more than acquisition of genes encoding the known toxins LT and
ST, which are invariably carried on plasmids, may be sufficient for
E. coli to effectively deliver these toxins to enterocytes (37). Simi-
larly, it has been suggested that commensal E. coli may act as “ge-
netic sinks” for pathogen evolution (30). The results of the present
studies support these hypotheses.
By assimilating the yghJ gene and downstream elements encod-
ing the type II secretion system (T2SS) from commensal strains,
ETEC strains have ensured both the secretion of LT via the T2SS
and its ultimate delivery to epithelial receptors through the muci-
nase activity of a second T2SS effector, YghJ. Interestingly, while
commensal strains produce and secrete small amounts of YghJ,
only ETEC exported this protein in abundance. Therefore, ETEC
might gain competitive access to enterocytes by optimizing export
of this mucin-degrading protein.
FIG 8 YghJ leads to enhanced cAMP activation in target intestinal epithelial cells. (a to l) Confocal immunofluorescence images of cAMP produced in small
intestinal epithelial cells of mice challenged with wild-type (wt) ETEC H10407 (a to d), the yghJ mutant (e to h), or mock-infected, PBS-challenged control mice
(i to l). (m) Quantification of cAMP fluorescence per epithelial cell. The dotted horizontal lines and the solid horizontal line represent geometric mean levels. The
values for the wt and yghJ groups were statistically significant by Mann-Whitney (two-tailed) nonparametric comparison (P 0.02).
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YghJ belongs to a large and diverse family of eukaryotic and
prokaryotic proteins containing putative metalloprotease do-
mains (38). Interestingly, enhancin, the prototype molecule of the
family of proteases most closely related to YghJ, was isolated from
an insect virus and targets insect intestinal mucins (35, 39). It
bears a canonical HEXXH metalloprotease motif within a domain
(M60-like pfam13402) that is strongly associated with pathogens
and commensal organisms that colonize mucosal surfaces (40).
The significant homology between YghJ and V. cholerae AcfD
(34) is worthy of comment. AcfD has antivibriocidal activity (33)
and is required for efficient intestinal colonization of Vibrio chol-
erae (34). Given the presence of an enhancin-like protease do-
main, it has been suggested that AcfD is a mucinase (40). To our
knowledge, this has not been tested experimentally. AcfD along
with two other lipoproteins encoded by V. cholerae, TcpC, and
ToxR-activated gene A (TagA), are regulated by the ToxR viru-
lence regulon (33). Interestingly, TagA (23), encoded on the same
V. cholerae pathogenicity island (VPI) that encodes AcfD (41),
also is a secreted mucinase. Notably, the hemagglutinin protease
of V. cholerae is also a mucinase that is secreted via the T2SS (42,
43), responsible for secretion of cholera toxin (CT). Therefore, V.
cholerae appears to be equipped with multiple enzymes with the
ability to degrade intestinal mucins, and similar to ETEC, it uses
the T2SS to export both an enterotoxin and one or more muci-
nases that facilitate the delivery of toxin.
The identification of YghJ homologues in a variety of enteric
pathogens with known mucinases might suggest that multiple
mucin-degrading enzymes could contribute cooperatively to vir-
ulence. A variety of different diarrheagenic E. coli produce muci-
nases (44–46), and the recent O104:H4 outbreak strain, also car-
ries the gene that encodes Pic, an established mucinase shared by
enteroaggregative E. coli and Shigella flexneri (44, 47, 48). Interest-
ingly, mucinase activity of Pic and other molecules was established
initially with readily available bovine submaxillary mucin (44).
However, YghJ had no demonstrable activity against this material,
suggesting structural and functional differences in mucinases.
Finding other mucinases with different substrate specificities in
these pathotypes raises the possibility that other molecules in ad-
dition to YghJ that degrade mucin exist in ETEC.
This concept is supported by our accompanying paper (60),
which demonstrates that many ETEC strains which secrete the
YghJ metalloprotease also secrete EatA, a plasmid-encoded serine
protease (7) with MUC2-degrading enzymatic activity.
These enzymes are part of a dynamic complex between ETEC
and the mucosa. Interestingly, elevations in intracellular cAMP
have been associated with commensurate increases in mucin se-
cretion by enterocytes (49), suggesting that LT, which exerts its
toxic effect by stimulating production of this cyclic nucleotide,
may itself be a mucin secretagogue. In addition, a wide variety of
microbial products or pathogen-associated molecular patterns
stimulate production, release, or altered glycosylation of mucins
(50). Therefore, it is not surprising that some enteric pathogens
make multiple enzymes to subvert this dynamic barrier.
Both intestinal commensal organisms and enteric pathogens
must interact with mucins to thrive in their intestinal niche. E. coli
(51) and other enteric pathogens such as Yersinia enterocolitica
(52) can bind to intestinal mucus and isolated mucus-derived
proteins (53), and this may be mediated in part by lipopolysaccha-
ride (LPS) on the surfaces of the organisms. The present studies
suggest that ETEC bacteria interact specifically with MUC2, the
major intestinal mucin, and that MUC2 appears to colocalize with
oligosaccharide of LPS on ETEC. The apparent coating of organ-
isms with MUC2 raises questions regarding the role it could play
in modulating both innate and adaptive immune responses to
these organisms. YghJ and other mucin-degrading enzymes may
allow ETEC and other pathogens to exploit these interactions.
As our understanding of ETEC pathogenesis evolves, new ap-
proaches to vaccine development emerge (5, 54, 55). Likewise,
current information regarding the nature of E. coli commensalism
in the intestine is inadequate, illustrated by the very limited num-
ber of “commensal” genomes presently available. Given the ap-
parent paucity of pathotype-specific vaccine targets, it will be im-
portant to determine whether highly conserved antigens such as
YghJ could be effectively targeted as vaccine candidates.
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